Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate a new diagnostic imaging test, positron emission tomography (PET), with a different radioactive form of iodine called iodine-124. This form is able to accurately measure the amount of radioactive iodine uptake in the cancer. If the new test determines sufficient radioiodine uptake in the cancer, treatment will continue as usual. However, if the new test shows only low radioiodine uptake, a decision may be made that the benefit from radioiodine therapy is insufficient and that another form of therapy is preferred.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Start Date
August 21, 2018
Primary Completion Date
August 1, 2027
Completion Date
August 1, 2027
Last Updated
March 20, 2026
60
ESTIMATED participants
PET/CT Scan
DEVICE
Iodine-124
DRUG
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06790706